Research shows that a test tablet with 10 mg dapagliflozin and 1000 mg metformin releases both medicines into the bloodstream at levels comparable to the reference version, with or without food. According to research reviewed by Gram, the key measurements for both medicines fell within the accepted equivalence range under fasting and fed conditions.
According to research reviewed by Gram, a test tablet combining 10 mg of dapagliflozin and 1000 mg of metformin works in the body much like the reference product it was compared against. Researchers gave healthy volunteers one tablet on an empty stomach and another after a meal, then measured how much medicine entered the bloodstream and how quickly it peaked. Under both conditions, the key measurements for both medicines fell within the accepted range for equivalence. Food changed the pattern slightly: dapagliflozin’s peak was a bit lower with a meal, and metformin peaked later. Overall exposure stayed similar, and the researchers reported no clinically meaningful differences in safety or tolerability. The study suggests the test tablet performs comparably to the reference product, though it measured how the body absorbs the medicine in healthy people rather than how well it controls blood sugar over time.
Key Statistics
A 2026 bioequivalence study published in Clinical Pharmacology in Drug Development found that fasting total dapagliflozin exposure was about 4.7% higher with a test tablet containing 10 mg dapagliflozin and 1000 mg metformin than with the reference product, a difference within the accepted equivalence range.
In the same 2026 study, the 90% confidence intervals for total exposure and peak levels of both dapagliflozin and metformin fell within the bioequivalence range under both fasting and fed conditions.
The 2026 study reported no clinically meaningful differences in safety or tolerability between the test and reference combination tablets in the healthy participants tested.
The Quick Take
- What they studied: Whether a tablet combining two diabetes medicines, dapagliflozin and metformin, releases the same amount of medicine into the blood as the reference version, both on an empty stomach and after eating.
- Who participated: Healthy volunteers. The exact number of participants was not reported in the information available for this summary.
- Key finding: Both tablets produced very similar medicine levels in the blood. Under fasting and fed conditions, the measured values for both medicines fell within the accepted equivalence range. For example, total metformin exposure was about 3% higher with the test tablet when taken on an empty stomach, a difference that stayed within the allowed limits.
- What it means for you: The research suggests this combination tablet is absorbed about the same way as the reference version. Food may shift the timing of absorption slightly, so follow your prescriber’s instructions about when to take it. This study looked at absorption in healthy people, so it does not show how the tablet affects blood sugar.
The Research Details
The researchers ran two separate trials. One tested the tablets on an empty stomach, and the other tested them after a meal. In each trial, participants took one version of the tablet, then, after a rest period, took the other version. This crossover approach lets each person serve as their own comparison, which helps reduce differences caused by body size, metabolism, or other individual traits.
After each dose, blood samples were collected over time to measure how much dapagliflozin and metformin entered the bloodstream. The team looked at three main measures: total exposure over the sampling period (AUC), the highest blood level reached (Cmax), and how long it took to reach that peak (tmax). They then compared the test and reference versions using a statistical range called a 90% confidence interval. Under the standard approach used for these studies, the results count as equivalent when this range falls within roughly 80% to 125% of the reference product.
Because the tablets were tested in both fasting and fed conditions, the study also checked whether a meal changes how the medicines behave. This matters because people take these medicines with and without food in daily life, and the pattern of absorption can affect how a product performs.
Combination tablets can make treatment simpler by reducing the number of pills a person must take each day. Before a combination product can be considered interchangeable with a reference product, regulators and researchers need to confirm that the body absorbs both medicines in a similar way. A crossover design with fasting and fed testing gives a clear, direct comparison under the conditions people actually use, which makes the findings more useful than a single test under one condition.
The study was published in a peer-reviewed journal, and its design is a recognized standard for comparing drug formulations. The crossover structure and use of established measurement methods are strengths. However, the number of participants was not reported in the information available for this summary, so it is hard to judge how precise the estimates are. The journal’s impact factor could not be verified here. These trials measure how the body processes the medicine, not whether it improves health outcomes, so the findings should be read as strong evidence of formulation similarity rather than proof of clinical benefit.
What the Results Show
Under fasting conditions, the test tablet produced dapagliflozin total exposure of 337.1 ng h/mL, compared with 321.9 ng h/mL for the reference, a difference of about 4.7%. Its highest dapagliflozin level was 96.6 ng/mL versus 101.3 ng/mL for the reference, about 4.7% lower. Both differences fell within the accepted equivalence range.
For metformin under fasting conditions, the test tablet reached a total exposure of 7,237.4 ng h/mL, compared with 7,009.9 ng h/mL for the reference, about 3.2% higher. Its peak level was 1,082.0 ng/mL versus 1,055.1 ng/mL, about 2.5% higher. Again, these differences stayed within the range the researchers used to define equivalence.
When the tablets were taken with food, the overall pattern shifted slightly. Dapagliflozin showed similar total exposure but a somewhat lower peak level. Metformin reached a similar peak but at a slightly later time, with higher total exposure values. The researchers reported that the 90% confidence intervals for total exposure and peak levels for both medicines fell within the bioequivalence range under both conditions.
Based on these measurements, the authors concluded that the two products are bioequivalent. In plain terms, the test tablet appears to deliver both medicines to the bloodstream in a way that is close enough to the reference product to be considered interchangeable from a absorption standpoint.
The researchers reported no clinically meaningful differences in safety or tolerability between the test and reference tablets. This suggests that, in these healthy volunteers, the two products caused similar side effects at the single doses tested. Because the study used one dose per visit in healthy participants, it cannot fully show how side effects might compare over weeks of daily use in people with diabetes.
Bioequivalence testing of this type is a standard step when a new or alternative version of a medicine is developed. Earlier research established how dapagliflozin and metformin behave individually, including how food can affect metformin absorption. This study builds on that work by testing the two medicines together in a fixed-dose combination, which is a more specific question than testing each drug alone.
The study measured medicine levels in healthy volunteers after a single dose, not in people who take these medicines daily for diabetes. It does not tell us how blood sugar, kidney function, or long-term safety would compare. The number of participants was not reported in the information available here, which makes it harder to judge the precision of the estimates. The study also tested only one strength combination (10 mg dapagliflozin with 1000 mg metformin), so the results may not apply directly to other strengths. Finally, the findings are based on a published abstract, so details in the full paper, such as the exact confidence intervals, could add useful context.
The Bottom Line
Research shows that the test combination tablet is absorbed in a way that is equivalent to the reference product, both on an empty stomach and with food. Confidence in this conclusion is high for absorption similarity, since the study used a standard design and reported that all key measures fell within accepted limits. Confidence is lower for predictions about blood sugar control or long-term outcomes, because this study did not measure those. Anyone considering a switch between versions should discuss it with a prescriber or pharmacist.
People prescribed dapagliflozin and metformin in combination, pharmacists, prescribers, and anyone comparing formulations for use in diabetes care may find these results useful. People who take these medicines separately, or who have kidney problems, a history of ketoacidosis, or other conditions that affect treatment, should talk with their healthcare provider before making any change. This summary does not replace individualized medical advice.
Absorption differences measured in this study occur within hours of a single dose. Any effect on blood sugar or other health markers develops over days to weeks of consistent daily use, and the full benefit of diabetes treatment is usually judged over several months with regular checkups. Because this study measured only single-dose absorption, it cannot predict how quickly any patient would notice changes in their health.
Frequently Asked Questions
Does the dapagliflozin and metformin combination tablet work the same as the reference version?
Research shows the test combination tablet releases both medicines into the blood at levels close to the reference product. In a 2026 study using 10 mg dapagliflozin and 1000 mg metformin, differences in key measures were roughly 2 to 5 percent and stayed within accepted equivalence limits under both fasting and fed conditions.
Does eating food change how dapagliflozin and metformin combination tablets are absorbed?
Food slightly changed the absorption pattern in a 2026 study without changing overall exposure in a meaningful way. With a meal, dapagliflozin peak levels were a bit lower, and metformin peaked later with somewhat higher total exposure. Both products were still considered bioequivalent under fed and fasting conditions.
Can a dapagliflozin and metformin combination tablet be swapped for the reference version?
A 2026 bioequivalence study concluded the test tablet is comparable to the reference version in how the body absorbs it, with no clinically meaningful differences in safety or tolerability observed. Any switch should still be discussed with a doctor or pharmacist, since the study tested healthy volunteers after a single dose.
What is a bioequivalence study and why do drug makers run them?
Bioequivalence studies check whether an alternative version of a medicine delivers the same active ingredient into the bloodstream at a similar amount and speed as the reference product. Testing under fasting and fed conditions, as in this 2026 dapagliflozin and metformin study, helps confirm consistent performance in everyday use.
Want to Apply This Research?
- Log each dose with the date, time, and whether it was taken with a meal or on an empty stomach. Add a short note on any side effects such as stomach upset, dizziness, or unusual tiredness, rating severity from 1 to 5. Review these entries weekly to spot patterns related to food timing.
- Set a daily reminder at the same time, and pair the dose with a consistent meal or a consistent empty-stomach routine, based on your prescriber’s instructions. Keeping timing steady makes it easier to notice any pattern that may relate to food. Share your log with your healthcare provider at each visit.
- Track dosing consistency, meal timing, and side effects over several months, and record any blood sugar readings your provider has asked you to monitor. Compare trends at each checkup rather than reacting to single readings. Ask your provider which measures matter most for your situation, and update the log whenever a prescription or formulation changes.
This article summarizes a bioequivalence study conducted in healthy participants and is provided for general information only. It does not replace advice from a doctor, pharmacist, or other licensed healthcare professional. Do not start, stop, or change dapagliflozin, metformin, or any combination product without first talking with your healthcare provider, and ask how food and timing should affect your specific prescription.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.